Canada · Health Canada Drug Product Database

MYLAN-NAPROXEN/ESOMEPRAZOLE MR

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference: 92813
DIN: 02443449
Form: Tablet (Immediate- And Delayed-Release)
Company as listed by source: MYLAN PHARMACEUTICALS ULC
Source status: Marketed (2017-02-10)
Source last updated: 2026-08-17

Source-listed ingredients

NAPROXEN — 500 MG
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) — 20 MG

These values do not establish equivalence or a dose recommendation.

Packages

60/100/500

Source and coverage

Open Health Canada Drug Product Database →

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse Canada records →